These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
114 related items for PubMed ID: 10566184
21. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery]. MMW Fortschr Med; 2003 Dec 18; 145(51-52):41. PubMed ID: 14974333 [No Abstract] [Full Text] [Related]
22. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Schleinitz MD, Weiss JP, Owens DK. Am J Med; 2004 Jun 15; 116(12):797-806. PubMed ID: 15178495 [Abstract] [Full Text] [Related]
23. Sirolimus for below the knee lesions: mid-term results of SiroBTK study. Commeau P, Barragan P, Roquebert PO. Catheter Cardiovasc Interv; 2006 Nov 15; 68(5):793-8. PubMed ID: 17039538 [Abstract] [Full Text] [Related]
24. Peripheral arterial disease: a review of disease awareness and management. Watson K, Watson BD, Pater KS. Am J Geriatr Pharmacother; 2006 Dec 15; 4(4):365-79. PubMed ID: 17296541 [Abstract] [Full Text] [Related]
25. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. WAVE Investigators. Am Heart J; 2006 Jan 15; 151(1):1-9. PubMed ID: 16368284 [Abstract] [Full Text] [Related]
26. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Mehta SR, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. Eur Heart J; 2000 Dec 15; 21(24):2033-41. PubMed ID: 11102254 [Abstract] [Full Text] [Related]
27. Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? Milani RV. Catheter Cardiovasc Interv; 2009 Jul 01; 74 Suppl 1():S7-S11. PubMed ID: 19213064 [Abstract] [Full Text] [Related]
28. Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor. Vilahur G, Pena E, Padró T, Badimon L. Thromb Haemost; 2007 Apr 01; 97(4):650-7. PubMed ID: 17393029 [Abstract] [Full Text] [Related]
29. Medical treatment of peripheral arterial disease: a comprehensive review. Stoyioglou A, Jaff MR. J Vasc Interv Radiol; 2004 Nov 01; 15(11):1197-207. PubMed ID: 15525738 [Abstract] [Full Text] [Related]
30. Combination antiplatelet agents in ischemic cerebrovascular disease. Moussouttas M, Papamitsakis N. Mt Sinai J Med; 2005 Jan 01; 72(1):16-22. PubMed ID: 15682258 [Abstract] [Full Text] [Related]
31. Antithrombotic therapy in peripheral arterial disease. Lipsitz EC, Kim S. Cardiol Clin; 2008 May 01; 26(2):289-98, vii. PubMed ID: 18407001 [Abstract] [Full Text] [Related]
35. [Effect of calciparine in the mid-term treatment of peripheral arteriopathy of the lower extremities]. Stanzani M, Colombo L, Altomare S, Pagnozzi G, Barbieri C, Bruschi R, Pietrasanta E. Minerva Cardioangiol; 1993 Oct 01; 41(10):465-8. PubMed ID: 8302443 [Abstract] [Full Text] [Related]